Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25276242 | 0.83 | KRAS (0.41) | MEN1KMT2AHSD17B10AKT1KRAS | |
| SCHEMBL25225518 | 0.81 | HSD17B10 (0.36) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL30455740 | 0.81 | HTT (0.44) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL25222339 | 0.81 | HTT (0.44) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL25225586 | 0.81 | MEN1 (0.40) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL25278259 | 0.80 | HTT (0.43) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL25270708 | 0.80 | MEN1 (0.40) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL25231891 | 0.78 | AKT1 (0.38) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL30406325 | 0.78 | KIT (0.41) | MEN1KMT2AKRAS | |
| SCHEMBL30404904 | 0.78 | HTT (0.39) | MEN1KMT2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | MEN1 2/4885KMT2A 8/4885ALDH1A1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.